{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T06:02:52Z","timestamp":1794549772846,"version":"4.9.1"},"reference-count":57,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2020,10,31]],"date-time":"2020-10-31T00:00:00Z","timestamp":1604102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["10650 and 10851"],"award-info":[{"award-number":["10650 and 10851"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Patients with well-differentiated thyroid cancer, especially papillary thyroid cancer (PTC), are treated with surgical resection of the thyroid gland. This is followed by post-operative radioactive iodine (I131), resulting in total thyroid ablation. Unfortunately, about 15-33% of PTC patients are unable to take up I131, limiting further treatment options. The aim of our study was to develop a cancer organoid model with the potential for pre-treatment diagnosis of these I131-resistant patients. PTC tissue from thirteen patients was used to establish a long-term organoid model. These organoids showed a self-renewal potential for at least five passages, suggesting the presence of cancer stem cells. We demonstrated that thyroid specific markers, a PTC marker, and transporters\/receptors necessary for iodine uptake and thyroid hormone production were expressed on a gene and protein level. Additionally, we cultured organoids from I131-resistant PTC material from three patients. When comparing PTC organoids to radioactive iodine (RAI)-refractory disease (RAIRD) organoids, a substantial discordance on both a protein and gene expression level was observed, indicating a treatment prediction potential. We showed that patient-derived PTC organoids recapitulate PTC tissue and a RAIRD phenotype. Patient-specific PTC organoids may enable the early identification of I131-resistant patients, in order to reduce RAI overtreatment and its many side effects for thyroid cancer patients.<\/jats:p>","DOI":"10.3390\/cancers12113212","type":"journal-article","created":{"date-parts":[[2020,10,31]],"date-time":"2020-10-31T21:39:56Z","timestamp":1604180396000},"page":"3212","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Patient-Derived Papillary Thyroid Cancer Organoids for Radioactive Iodine Refractory Screening"],"prefix":"10.3390","volume":"12","author":[{"given":"Luc H.J.","family":"Sondorp","sequence":"first","affiliation":[{"name":"Department of Surgical Oncology, University of Groningen, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands"},{"name":"Department of Biomedical Sciences of Cell &amp; Systems\u2013Section Molecular Cell Biology, University of Groningen, University Medical Center Groningen, 9700 RB Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0781-1837","authenticated-orcid":false,"given":"Vivian M.L.","family":"Ogundipe","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences of Cell &amp; Systems\u2013Section Molecular Cell Biology, University of Groningen, University Medical Center Groningen, 9700 RB Groningen, The Netherlands"},{"name":"Department of Radiation Oncology, University of Groningen, University Medical Center Groningen, 9700 RB Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andries H.","family":"Groen","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, University of Groningen, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands"},{"name":"Department of Biomedical Sciences of Cell &amp; Systems\u2013Section Molecular Cell Biology, University of Groningen, University Medical Center Groningen, 9700 RB Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Kelder","sequence":"additional","affiliation":[{"name":"Department of Surgery, Martini Hospital, 9728 NT Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7308-9937","authenticated-orcid":false,"given":"Annelies","family":"Kemper","sequence":"additional","affiliation":[{"name":"Department of Surgery, Treant Hospital, 7909 AA Hoogeveen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thera P.","family":"Links","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, University of Groningen, University Medical Center Groningen, 9700 RB Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5503-1064","authenticated-orcid":false,"given":"Robert P.","family":"Coppes","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences of Cell &amp; Systems\u2013Section Molecular Cell Biology, University of Groningen, University Medical Center Groningen, 9700 RB Groningen, The Netherlands"},{"name":"Department of Radiation Oncology, University of Groningen, University Medical Center Groningen, 9700 RB Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Schelto","family":"Kruijff","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, University of Groningen, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,10,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3803\/EnM.2018.33.2.185","article-title":"Management of Low-Risk Papillary Thyroid Cancer","volume":"33","author":"Brito","year":"2018","journal-title":"Endocrinol. Metab."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1530\/ERC-12-0336","article-title":"Rising incidence, no change in survival and decreasing mortality from thyroid cancer in The Netherlands since 1989","volume":"20","author":"Husson","year":"2013","journal-title":"Endocr.-Relat. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1089\/thy.2015.0116","article-title":"The Impact of Diagnostic Changes on the Rise in Thyroid Cancer Incidence: A Population-Based Study in Selected High-Resource Countries","volume":"25","author":"Vaccarella","year":"2015","journal-title":"Thyroid"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States","volume":"74","author":"Rahib","year":"2014","journal-title":"Cancer Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1093\/annonc\/mdt301","article-title":"Cancer mortality in Europe, 2005\u20132009, and an overview of trends since 1980","volume":"24","author":"Bosetti","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1177\/2042018811419889","article-title":"Thyroid cancer: Pathogenesis and targeted therapy","volume":"2","author":"Liebner","year":"2011","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMp1604412","article-title":"Worldwide Thyroid-Cancer Epidemic? The Increasing Impact of Overdiagnosis","volume":"375","author":"Vaccarella","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11864-005-0012-3","article-title":"Overview of the management of differentiated thyroid cancer","volume":"6","author":"Fernandes","year":"2005","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.2147\/OTT.S160752","article-title":"The role of radioactive iodine therapy in papillary thyroid cancer: An observational study based on SEER","volume":"11","author":"Tang","year":"2018","journal-title":"OncoTargets Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1007\/s00259-008-0883-1","article-title":"Guidelines for radioiodine therapy of differentiated thyroid cancer","volume":"35","author":"Luster","year":"2008","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Nixon, I., Haugen, B.R., Alexander, E.K., Bible, K.C., Doherty, G.M., Mandel, S.J., Nikiforov, Y.E., Pacini, F., Randolph, G.W., and Sawka, A.M. (2015). Faculty Opinions recommendation of 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Fac. Opin.\u2013Post-Publ. Peer Rev. Biomed. Lit., 26.","DOI":"10.3410\/f.725851631.793511558"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1586\/eem.12.36","article-title":"Radioactive iodine-refractory differentiated thyroid cancer: Unmet needs and future directions","volume":"7","author":"Pacini","year":"2012","journal-title":"Expert Rev. Endocrinol. Metab."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1210\/jc.2005-2838","article-title":"Long-Term Outcome of 444 Patients with Distant Metastases from Papillary and Follicular Thyroid Carcinoma: Benefits and Limits of Radioiodine Therapy","volume":"91","author":"Durante","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s11912-018-0736-4","article-title":"Radioactive Iodine-Refractory Differentiated Thyroid Cancer in the Elderly","volume":"20","author":"Gosain","year":"2018","journal-title":"Curr. Oncol. Rep."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1530\/EC-17-0302","article-title":"NIS expression in thyroid tumors, relation with prognosis clinicopathological and molecular features","volume":"7","author":"Tavares","year":"2018","journal-title":"Endocr. Connect."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3389\/fendo.2017.00260","article-title":"Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer for Reapplication of I-131 Therapy","volume":"8","author":"Hong","year":"2017","journal-title":"Front. Endocrinol."},{"key":"ref_17","first-page":"1","article-title":"Personalized Medicine Based on Theranostic Radioiodine Molecular Imaging for Differentiated Thyroid Cancer","volume":"2016","author":"Ahn","year":"2016","journal-title":"BioMed Res. Int."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.ctrv.2015.09.001","article-title":"Intermediate and long-term adverse effects of radioiodine therapy for differentiated thyroid carcinoma\u2013A systematic review","volume":"41","author":"Clement","year":"2015","journal-title":"Cancer Treat. Rev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1210\/jc.2015-2124","article-title":"Bone marrow function after 131 I therapy in patients with differentiated thyroid carcinoma","volume":"100","author":"Prinsen","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-019-5465-z","article-title":"A novel microfluidic device capable of maintaining functional thyroid carcinoma specimens ex vivo provides a new drug screening platform","volume":"19","author":"Riley","year":"2019","journal-title":"BMC Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.cell.2015.03.053","article-title":"Prospective derivation of a living organoid biobank of colorectal cancer patients","volume":"161","author":"Francies","year":"2015","journal-title":"Cell"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.semcancer.2018.06.005","article-title":"Patient-derived tumor organoids for prediction of cancer treatment response","volume":"53","author":"Nagle","year":"2018","journal-title":"Semin. Cancer Biol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"13308","DOI":"10.1073\/pnas.1516689112","article-title":"Preserved genetic diversity in organoids cultured from biopsies of human colorectal cancer metastases","volume":"112","author":"Weeber","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1038\/s41591-019-0584-2","article-title":"A rectal cancer organoid platform to study individual responses to chemoradiation","volume":"25","author":"Ganesh","year":"2019","journal-title":"Nat. Med."},{"key":"ref_25","unstructured":"Yao, Y., Xu, X., Yang, L., Zhu, J., Wan, J., Shen, L., Xia, F., Fu, G., Deng, Y., and Pan, M. (2019). Faculty Opinions recommendation of Patient-Derived Organoids Predict Chemoradiation Responses of Locally Advanced Rectal Cancer. Fac. Opin.\u2013Post-Publ. Peer Rev. Biomed. Lit."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1126\/science.aao2774","article-title":"Patient-derived organoids model treatment response of metastatic gastrointestinal cancers","volume":"359","author":"Vlachogiannis","year":"2018","journal-title":"Science"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1158\/2159-8290.CD-18-0349","article-title":"Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer","volume":"8","author":"Tiriac","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-11867-6","article-title":"Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening","volume":"10","author":"Kim","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.stemcr.2014.09.015","article-title":"Purification and Ex Vivo Expansion of Fully Functional Salivary Gland Stem Cells","volume":"3","author":"Nanduri","year":"2014","journal-title":"Stem Cell Rep."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"16970","DOI":"10.1073\/pnas.0808616105","article-title":"Wnt-mediated self-renewal of neural stem\/progenitor cells","volume":"105","author":"Kalani","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_31","first-page":"1003","article-title":"Identification of stem cells in small intestine and colon by marker gene Lgr5","volume":"449","author":"Barker","year":"2007","journal-title":"Nat. Cell Biol."},{"key":"ref_32","first-page":"247","article-title":"In vitro expansion of single Lgr5+ liver stem cells induced by Wnt-driven regeneration","volume":"494","author":"Huch","year":"2013","journal-title":"Nat. Cell Biol."},{"key":"ref_33","first-page":"133","article-title":"Thyroid cancer cell lines: An overview","volume":"3","author":"Esaiselet","year":"2012","journal-title":"Front. Endocrinol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Hanly, E.K., Rajoria, S., Darzynkiewicz, Z., Zhao, H., Suriano, R., Tuli, N., George, A.L., Bednarczyk, R., Shin, E., and Geliebter, J. (2014). Disruption of mutated BRAF signaling modulates thyroid cancer phenotype. BMC Res. Notes, 7.","DOI":"10.1186\/1756-0500-7-187"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"67","DOI":"10.5858\/arpa.2014-0056-RA","article-title":"Application of Immunohistochemistry in Thyroid Pathology","volume":"139","author":"Liu","year":"2015","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4274\/2017.26.suppl.10","article-title":"Tiroid Stimulan Hormon Resept\u00f6r\u00fc","volume":"26","author":"Tuncel","year":"2017","journal-title":"Mol. Imaging Radionucl. Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"81","DOI":"10.4331\/wjbc.v8.i1.81","article-title":"Use of thyroglobulin as a tumour marker","volume":"8","author":"Indrasena","year":"2017","journal-title":"World J. Biol. Chem."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0344-0338(99)80017-X","article-title":"Overexpression of c-Met Protein in Human Thyroid Tumors Correlated with Lymph Node Metastasis and Clinicopathologic Stage","volume":"195","author":"Chen","year":"1999","journal-title":"Pathol.-Res. Pr."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1210\/er.2001-0029","article-title":"The Sodium\/Iodide Symporter (NIS): Characterization, Regulation, and Medical Significance","volume":"24","author":"Paroder","year":"2003","journal-title":"Endocr. Rev."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"526","DOI":"10.3389\/fendo.2019.00526","article-title":"Identification of Two Missense Mutations in DUOX1 (p.R1307Q) and DUOXA1 (p.R56W) That Can Cause Congenital Hypothyroidism Through Impairing H2O2 Generation","volume":"10","author":"Liu","year":"2019","journal-title":"Front. Endocrinol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Presta, I., Arturi, F., Ferretti, E., Mattei, T., Scarpelli, D., Tosi, E., Scipioni, A., Celano, M., Gulino, A., and Filetti, S. (2005). Recovery of NIS expression in thyroid cancer cells by overexpression of Pax8 gene. BMC Cancer, 5.","DOI":"10.1186\/1471-2407-5-80"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.redox.2017.09.013","article-title":"Autophagy regulates DUOX1 localization and superoxide production in airway epithelial cells during chronic IL-13 stimulation","volume":"14","author":"Dickinson","year":"2018","journal-title":"Redox Biol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1083\/jcb.107.6.2389","article-title":"Localization of the tight junction protein, ZO-1, is modulated by extracellular calcium and cell-cell contact in Madin-Darby canine kidney epithelial cells","volume":"107","author":"Siliciano","year":"1988","journal-title":"J. Cell Biol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1083\/jcb.200612080","article-title":"Requirement of ZO-1 for the formation of belt-like adherens junctions during epithelial cell polarization","volume":"176","author":"Ikenouchi","year":"2007","journal-title":"J. Cell Biol."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Kim, H., Phung, Y., and Ho, M. (2012). Changes in Global Gene Expression Associated with 3D Structure of Tumors: An Ex Vivo Matrix-Free Mesothelioma Spheroid Model. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0039556"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Colella, G., Fazioli, F., Gallo, M., De Chiara, A., Apice, G., Ruosi, C., Cimmino, A., and De Nigris, F. (2018). Sarcoma Spheroids and Organoids\u2014Promising Tools in the Era of Personalized Medicine. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19020615"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"eaay2574","DOI":"10.1126\/scitranslmed.aay2574","article-title":"Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients","volume":"11","author":"Ooft","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/gastro\/goy040","article-title":"Patient-derived organoids: A promising model for personalized cancer treatment","volume":"6","author":"Yang","year":"2018","journal-title":"Gastroenterol. Rep."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/s41416-019-0616-1","article-title":"Patient-derived organoids as a potential model to predict response to PD-1\/PD-L1 checkpoint inhibitors","volume":"121","author":"Scognamiglio","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"127","DOI":"10.4068\/cmj.2019.55.3.127","article-title":"Identification of Radioactive Iodine Refractory Differentiated Thyroid Cancer","volume":"55","author":"Mu","year":"2019","journal-title":"Chonnam Med. J."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s12253-008-9031-2","article-title":"Different Expression of Occludin and ZO-1 in Primary and Metastatic Liver Tumors","volume":"14","author":"Szabo","year":"2008","journal-title":"Pathol. Oncol. Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1016\/S0002-9440(10)65691-X","article-title":"Loss of the Tight Junction MAGUK ZO-1 in Breast Cancer","volume":"153","author":"Hoover","year":"1998","journal-title":"Am. J. Pathol."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Catalanotto, C., Cogoni, C., and Zardo, G. (2016). MicroRNA in Control of Gene Expression: An Overview of Nuclear Functions. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17101712"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.cell.2009.09.013","article-title":"Regulating the Regulators: Posttranslational Modifications of RNA Silencing Factors","volume":"139","author":"Heo","year":"2009","journal-title":"Cell"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.tibtech.2017.12.005","article-title":"Personalized Cancer Medicine: An Organoid Approach","volume":"36","author":"Es","year":"2018","journal-title":"Trends Biotechnol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.chembiol.2017.06.012","article-title":"Tumor Organoids as a Pre-clinical Cancer Model for Drug Discovery","volume":"24","author":"Weeber","year":"2017","journal-title":"Cell Chem. Biol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"R307","DOI":"10.1530\/ERC-13-0187","article-title":"Metastatic mechanisms in follicular cell-derived thyroid cancer","volume":"20","author":"Phay","year":"2013","journal-title":"Endocr.-Relat. Cancer"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/11\/3212\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:27:32Z","timestamp":1760178452000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/11\/3212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,31]]},"references-count":57,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,11]]}},"alternative-id":["cancers12113212"],"URL":"https:\/\/doi.org\/10.3390\/cancers12113212","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,31]]}}}